Stability of adherence to highly active antiretroviral therapy over time among clients enrolled in the treatment adherence demonstration project

Journal of Acquired Immune Deficiency Syndromes

Volumn 33, Issue 4, 2003, Pages 484-493

  Tesoriero, James ^a   French, Tyler ^a   Weiss, Linda ^b   Waters, Mark ^a   Finkelstein, Ruth ^b   Agins, Bruce ^a  

^a NEW YORK STATE DEPARTMENT OF HEALTH   (United States)

^b NEW YORK ACADEMY OF MEDICINE   (United States)

Author keywords

Adherence; AIDS; Highly active antiretroviral therapy (HAART); HIV; Longitudinal study

Indexed keywords

ANTIRETROVIRUS AGENT;

ADULT; ANTIVIRAL ACTIVITY; ARTICLE; DRUG STABILITY; FEMALE; FOLLOW UP; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; SURVIVAL; VIRUS REPLICATION; VIRUS RESISTANCE;

EID: 0038298328     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/00126334-200308010-00009     Document Type: Article

References (55)

1. Palella FJ, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med. 1998;338:853-860.
2. Hogg RS, O'Shaughnessy MV, Gataric N, et al. Decline in deaths from AIDS due to new antiretrovirals. Lancet. 1997;349:1294.
3. Gulick RM, Mellors JW, Havlir D. et al. Treatment with Indinavir, Zidovudine, and Lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med. 1997;337:734-739.
4. Montaner JSG, Reiss P, Cooper D, et al. A randomized, double-blind trial comparing combinations of Nevirapine, Didanosine, and Zidovudine for HIV-infected patients. JAMA. 1998;279:930-937.
5. Maher K, Klimas N, Fletcher MA, et al. Disease progression, adherence, and response to protease inhibitor therapy for HIV infection in an urban Veterans Affairs medical center. J Acquir Immune Defic Syndr. 1999;22:358-363.
6. Hammer SM, Squires KE, Hughes MD, et al. A controlled trial of two nucleoside analogues plus Indinavir in persons with human immunodeficiency virus infection and cd4 cell counts of 200 per cubic millimeter or less. N Engl J Med. 1997;337:725-733.
7. The CASCADE Collaboration. Survival after introduction of HAART in people with known duration of HIV-1 infection. Lancet. 2000;355:1158-1159.
8. Mocroft A, Gill MJ, Davidson W, et al. Predictors of a viral response and subsequent virological treatment failure in patients with HIV starting a protease inhibitor. AIDS. 1998;12:2161-2167.
9. Panel on Clinical Practices for Treatment of HIV Infection. Department of Health and Human Services and Henry J. Kaiser Family Foundation. Guidelines for the use of antiretroviral agents in infected-infected adults and adolescents. February 4, 2002. Available at: http://www.hivatis.org/trtgdlns.html#Adult. Accessed February 15, 2002.
10. Carpenter CCJ, Cooper DA, Fischl MA, et al. Antiretroviral therapy in adults: updated recommendations of the international AIDS society-USA panel. JAMA. 2000;283:381-390.
11. Hecht FM, Colfax G, Swanson M, et al. Adherence and effectiveness of protease inhibitors in clinical practice [abstract 151]. Paper presented at: 5th Conference on Retroviruses and Opportunistic Infections; February 1-5, 1998; Chicago
12. Knobel H, Carmona A, Grau S, et al. Adherence and effectiveness of highly active antiretroviral therapy. Arch Intern Med. 1998:1953.
13. Bangsberg DR, Hecht FM, Charlebois ED, et al. Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population. AIDS. 2000;14:357-366.
14. Paterson DL, Swindells S, Mohr J, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med. 2000;133:21-30.
15. Deeks SG. Determinants of virological response to antiretroviral therapy: implications for long-term strategies. Clin Infect Dis. 2000;30(suppl 2):s177-s184.
16. McNabb J, Ross JW, Abriola K, et al. Adherence to highly active antiretroviral therapy predicts virologic outcome at an inner-city human immunodeficiency virus clinic. Clin Infect Dis. 2001;33:700-705.
17. Moing VL, Chêne G, Carrieri MP, et al. Clinical, biological, and behavioral predictors of early immunologic and virologic response in HIV-infected patients initiating protease inhibitors. J Acquir Immune Defic Syndr. 2001:27:372-376.
18. Bangsberg DR, Perry S, Charlebois ED, et al. Non-adherence to highly active antiretroviral therapy predicts progression to AIDS. AIDS. 2001;15:1181-1183.
19. Knobel H, Guelar A, Carmona A, et al. Virologic outcome and predictors of virologic failure of highly active antiretroviral therapy containing protease inhibitors. Aids Patient Care STDS. 2001;15:193-199.
20. Patterson D, Swindells S, Mohr J, et al. How much adherence is enough? A prospective study of adherence to protease inhibitor therapy using MEMSCaps [abstract]. Paper presented at: 6th Conference on Retroviruses and Opportunistic Infections; January 31-February 4, 1999; Chicago.
21. Low-Beer S, Yip B, O'Shaughnessy MV, et al. Adherence to triple therapy and viral load response. J Acquir Immune Defic Syndr. 2000;23:360-361.
22. Pomerantz RJ. Primary HIV-1 resistance: a new phase in the epidemic? JAMA. 1999;282:1177-1179.
23. Wainberg MA, Friedland G. Public health implications of antiretroviral therapy and HIV drug resistance. JAMA 1998;1977-1983.
24. Imrie A, Beveridge A, Genn W, et al. Transmission of human immunodeficiency virus type 1 resistant to nevirapine and zidovudine. J Infect Dis. 1997;175:1502-1506.
25. Aquila RT, Johnson VA, Welles SL, et al. Zidovudine resistance and HIV-1 disease progression during antiretroviral therapy. Ann Intern Med. 1995;122:401-408.
26. Erice A, Mayers DL, Strike DG, et al. Brief report: primary infection with zidovudine-resistant human immunodeficiency virus type 1. N Engl J Med. 1993;328:1163-1165.
27. Conway B, Montessori V, Rouleau D, et al. Primary lamivudine resistance in acute/early human immunodeficiency virus infection. Clin Infect Dis. 1999;28:910-911.
28. Hecht FM, Grant RM, Petropoulos CJ, et al. Sexual transmission of an HIV-1 variant resistant to multiple reverse-transcriptase and protease inhibitors. N Engl J Med. 1998;339:307-311.
29. Boden D, Hurley A, Zhang L, et al. HIV-1 drug resistance in newly infected individuals. JAMA. 1999;282:1135-1141.
30. Kleeberger CA, Phair JP, Strathdee SA, et al. Determinants of heterogeneous adherence to HIV-antiretroviral therapies in the multicenter AIDS cohort study. J Acquir Immune Defic Syndr. 2001;26:82-92.
31. Bartlett JA, Demasi R, Quinn J, et al. Overview of the effectiveness of triple combination therapy in antiretroviral-naïve HIV-1 infected adults. AIDS. 2001;15:1369-1377.
32. Catz SL, Kelly JA, Bogart LM, et al. Patterns, correlates, and barriers to medication adherence among persons prescribed new treatments for HIV disease. Health Psychol. 2000;19:124-133.
33. Max B, Sherer R. Management of adverse effects of antiretroviral therapy and medication adherence. Clin Infect Dis. 2000;30(suppl 2):S96-116.
34. Duran S, Saves M, Spire B, et al. Failure to maintain long-term adherence to highly active antiretroviral therapy: the role of lipodystrophy. AIDS. 2001;15:2441-2444.
35. Holzemer WL, Corless IB, Nokes KM, et al. Predictors of self-reported adherence in persons living with HIV disease. Aids Patient Care STDS. 1999;13:185-197.
36. Gordillo V, del Amo J, Soriano V, et al. Sociodemographic and psychological variables influencing adherence to antiretroviral therapy. AIDS. 1999;13:1763-1769.
37. Wenger N, Gifford A, Liu H, et al. Patient characteristics and attitudes associated with antiretroviral (AR) adherence [abstract 98]. Paper presented at: 6th Conference on Retroviruses and Opportunistic Infections; January 31-February 4, 1999; Chicago.
38. Chesney MA, Ickovics JR, Chambers DB, et al. Self-reported adherence to antiretroviral medications among participants in HIV clinical trials: the AACTG Adherence Instruments Patient Care Committee, Adherence Working Group of the Outcomes Committee of the AACTG. AIDS Care. 2000;12:255-266.
39. Singh N, Berman SM, Swindells S, et al. Adherence of human immunodeficiency virus-infected patients to antiretroviral therapy. Clin Infect Dis. 1999;29:824-830.
40. Stone VE. Strategies for optimizing adherence to highly active antiretroviral therapy: lessons from research and clinical practice. Clin Infect Dis. 2001;33:865-872.
41. Broers B, Morabia A, Hirschel B. A cohort study of drug users' compliance with Zidovudine treatment. Arch Intern Med. 1994;154:1121-1127.
42. Eldred LJ, Wu AW, Chaisson RE, et al. Adherence to antiretroviral and Pneumocystis prophylaxis in HIV disease. J Acquir Immune Defic Syndr. 1998;18:117-125.
43. Weidle PJ, Ganea CE, Irwin KL, et al. Adherence to antiretroviral medications in an inner-city population. J Acquir Immune Defic Syndr. 1999;22:498-502.
44. Stein MD, Rich JD, Maksad J, et al. Adherence to antiretroviral therapy among HIV-infected methadone patients: effect of ongoing illicit drug use. Ar J Drug Alcohol Abuse. 2000;26:195-205.
45. Gross R, Bilker WB, Friedman HM, et al. Effect of adherence to newly initiated antiretroviral therapy on plasma viral load. AIDS. 2001;15:2109-2117.
46. Roca B, Gómez CJ, Arnedo A. Adherence, side effects and efficacy of Stavudine plus Lamivudine plus Nelfinavir in treatment-experienced HIV-infected patients. J Infect. 2000;41:50-54.
47. Ostrop NJ, Hallet KA, Gill MJ. Long-term patient adherence to antiretroviral therapy. Ann Pharmacother. 2000;34:703-709.
48. Carrieri P, Cailleton V, Le Moing V, et al. The dynamic of adherence to highly active antiretroviral therapy: results from the French National APROCO cohort. J Acquir Immune Defic Syndr. 2001;28:232-239.
49. Miller LG, Hays RD. Adherence to combination antiretroviral therapy: synthesis of the literature and clinical implications. AIDS Reader. 2000;10:177-185.
50. Melbourne KM, Geletko SM, Brown SL, et al. Medication adherence in patients with HIV infection: a comparison of two measurement methods. AIDS Reader. 1999;9:329-338.
51. Lucas GM, Gebo KA, Chaisson RE, et al. Longitudinal assessment of the effects of drug and alcohol abuse on HIV-1 treatment outcomes in an urban clinic. AIDS. 2002;16:767-774.
52. Goodman L. Statistical methods for analyzing processes of change. Am J Sociol. 1962;68:57-78.
53. Eldred L. Adherence in the era of protease inhibitors. Hopkins HIV Rep. 1997;July:6-11.
54. Liu H, Golin CE, Miller LG, et al. A comparison study of multiple measures of adherence to HIV protease inhibitors. Ann Intern Med. 2001;134:968-977.
55. Wagner JH, Justice AC, Chesney M, et al. Patient and provider-reported adherence: towards a clinically useful approach to measuring antiretroviral adherence. J Clin Epidemiol. 2001;54: S91-S98.